title: Dose delivery late in the breath can increase dry powder aerosol penetration into the lungs.
abstract: In addition to aerosol particle size and mode of inhalation, the time-point of dose delivery during inhalation may be an important factor governing the intrapulmonary distribution of aerosolized drug. To generate different intrapulmonary deposition patterns of a drug model aerosol, a device with the capability of delivering small amounts of technetium-99m-labeled lactose dry powder at pre-set time-points during inhalation was developed. A single dose of the radioaerosol was delivered after inhalation of 20% (A) or 70% (B) of the vital capacity inhaled through the device. Twelve healthy subjects were studied in a randomized crossover fashion. Planar gamma scintigraphy was carried out, and the penetration index, PI, defined as the ratio of peripheral to central lung zone deposition of radioactivity, was estimated. A significant increase in PI from 3.0 (A) to 3.7 (B) was observed with the change from early to late delivery of the dose (p < 0.01). No difference in the total amount of radioactivity within the lungs could be detected. In conclusion, independent of total pulmonary deposition, deeper dry powder aerosol penetration into the lungs was found for the dose delivered at near end instead of at the beginning of inhalation. By computational modeling of the aerosol transport and deposition, that finding was mechanistically explained by differences in airway caliber as a consequence of the level of lung inflation at the time-point of dose delivery.
authors.affiliation: AstraZeneca R and D Lund, Sweden. Eva.Bondesson@astrazeneca.com
authors.forename: Eva
authors.initials: E
authors.lastname: Bondesson
authors.forename: Thomas
authors.initials: T
authors.lastname: Bengtsson
authors.forename: Lars
authors.initials: L
authors.lastname: Borgström
authors.forename: Lars-Erik
authors.initials: LE
authors.lastname: Nilsson
authors.forename: Kristina
authors.initials: K
authors.lastname: Norrgren
authors.forename: Bo
authors.initials: B
authors.lastname: Olsson
authors.forename: Mårten
authors.initials: M
authors.lastname: Svensson
authors.forename: Per
authors.initials: P
authors.lastname: Wollmer
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D018592:Cross-Over Studies; D006801:Humans; D007785:Lactose; D008168:Lung / Q000000981:diagnostic imaging / Q000378:metabolism*; D008297:Male; D008962:Models, Theoretical; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D011208:Powders; D011877:Radionuclide Imaging; D013667:Technetium
chemical_list: D000336:Aerosols; D011208:Powders; D013667:Technetium; D007785:Lactose